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Available online 6 May 2016The human embryonic stem cell line RCe013-A (RC-9) was derived under quality assured compliance with UK
regulation, EuropeanUnionDirectives and International guidance for tissue procurement, processing and storage
according toGoodManufacturing Practice (GMP) standards. The cell linewas derived from a failed to fertilise oocyte
voluntarily donated as unsuitable and surplus to fertility requirements following informed consent. RCe013-A (RC-
9) shows normal pluripotencymarker expression and differentiation to the three germ layers in vitro and in vivo. It
has a normal 46XY male karyotype and microsatellite PCR identity, HLA and blood group typing data are available.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource tableame of stem cell construct RCe013-A
lternative name RC-9, RC9
stitution Roslin Cells Ltd.
erson who created resource B. Tye, K. Bruce, P. Dand, G. Russell, D.M.
Collins, A. Greenshields, J. Marshall, K.
McDonald, H. Bradburn, M.A. Canhamontact person and email Paul.desousa@roslincells.com;
Paul.desousa@ed.ac.uk
Janet.downie@roslincells.com
Aidan.courtney@roslincells.com
Malcolm.bateman@roslinfoundation.com
Tilo.kunath@ed.ac.ukate archived/stock date 10 September 2014 (Seed lot, Passage 28)
ype of resource Biological reagent: cell line
ub-type hESC, clinical grade
rigin Zygote (Oocyte/1PN)
ey transcription factors Oct4 (conﬁrmed by ﬂow cytometry),
uthentication See Quality Control Certiﬁcate of Analysis
(Fig. 1)
nk to related literature (direct
URL links and full references)N/Aformation in public databases http://hpscreg.eu/cell-line/RCe013-A
thics Informed consent obtained. Scotland A Re-
search Ethics committee approval obtained
(07/MRE00/56). Conducted under the UK Hu-
man Fertilisation and Embryology Authority
licence no. R0136 to centre 0202 and UK Hu-
man Tissue Authority (HTA) licensing number
22631.. This is an open access article underResource details
RCe013-A (RC-9) was received as a failed to fertilise oocyte/1PN
(pro-nuclear) embryo that was surplus to requirement or unsuitable
for clinical use due to late development. Human embryonic stem cell
(hESC) isolation, expansion and qualiﬁcation was performed in a facili-
ties whose speciﬁcation, operation andmonitoring complied with GMP
standards enabling; i) a fully traceable procurement procedure with in-
formed ethical consent which includes provision for commercial use, ii)
detailed medical history and blood borne virus (BBV) screening of do-
nors, and iii) compilation of a cell line history providing details on
hESC manufacturing process and quality control testing regime.
Human ESC culture and processing was performed in a grade A tis-
sue culture cabinet in a grade B clean room environment monitored
for particulate and microbiological contamination during cell process-
ing in accordance with Rules and Guidance for Pharmaceutical Manu-
facturers and Distributors — The Orange Guide, compiled by the UK
Medicines Healthcare Products Regulatory Authority (Go to: https://
www.gov.uk/guidance/good-manufacturing-practice-and-good-
distribution-practice). Accordingly, the facility was operating under a
mature Quality Management System, compliant with ISO9001:2008
standards. Further hESC derivation was performed under licensure
from the UK HFEA (R0136 to centre 0202) and HTA (Licensing Number
22631).
The embryo was grown to blastocyst stage and the cell line was de-
rived by whole embryo outgrowth on mitotically inactivated human
dermal ﬁbroblast (HDF) feeder cells. HDFs were derived and
manufactured according to GMP and had been approved for clinicalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Quality Control Certiﬁcate of Analysis for RCe013-A (RC-9) P28 seed lot.
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HDFs, hESCs were grown in a xeno-free cell therapy grade media (XF
KODMEM) supplemented with xeno-free human recombinant bFGF.
HESCs were subsequently expanded in a GMP grade serum-free medi-
um (StemPro hESC Serum Free Medium,) and xeno-free matrix
(CellStart). The former contained bovine serum albumin (BSA) from a
Transmissible Spongioform Encephalopathy (TSE)-free country of ori-
gin. The cell line was cryopreserved in a GMP compliant cryopreserva-
tion solution (CryoStor CS10).
By ﬂow cytometry, RCe013-A (RC-9) expressed the pluripotency
makers Oct-4, Tra-1-60 and SSEA-4 (98.9%, 99.2% and 100.0%, respec-
tively), whereas low expression of the differentiation marker SSEA-1
(3.0%) was observed (Fig. 1, Fig. 2). Differentiation to the three germlayers, endoderm, ectoderm and mesoderm, was demonstrated using
embryoid body formation in vitro, and expression of the germ layer
markers α-fetoprotein, β-tubulin and muscle actin was observed
(Fig. 3, top panel). In vivo teratoma formation yielded typical hESC de-
rived teratomas. Histological examination of ﬁxed and stained sections
clearly showed generation of cell types from ectoderm and mesoderm
lineages. Endoderm differentiation was also present, but the quality of
the structures meant these could not be fully characterised (Fig. 3, bot-
tom panels).
A microsatellite PCR proﬁle has been obtained for the cell line, and
HLA Class I and II typing is available (Table 1). Blood group genotyping
gave the blood group BB (Table 1). The cell line is free frommycoplasma
contamination as determined by RT-qPCR.
Fig. 2. RCe013-A (RC-9) was subjected to ﬂow cytometry analysis for markers of pluripotencywith speciﬁc antibody (top row) or isotype control (bottom row) as indicated above the dot
plot. Percentage staining is indicated in the respective quadrants. This analysis was carried out at passage 31 during re-banking of the cell line.
Fig. 3. RCe013-A (RC-9) can differentiate into the three germ layers in vitro and in vivo. Embryoid body mediated differentiation (top panel) resulted in expression of β-tubulin III
(ectoderm), muscle actin (mesoderm), and α-fetoprotein (endoderm). Speciﬁc staining is shown in green, cell nuclei are counterstained with DAPI (blue). Histological sections of
teratomas formed under the kidney capsule of mice yielded clear evidence for mesoderm and ectoderm differentiation and indicated that endoderm structures were also present.
Tissue structures identiﬁed are indicated by arrows.
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Table 1
Microsatellite PCR, blood group and HLA tissue typing results for RCe013-A (RC-9).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2 D16S539 1 D16S539 2 D2S1338 1 D2S1338 2
15 16 15 18 12 12 18 23
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2 D21S11 1 D21S11 2 D18S51 1 D18S51 2
X Y 13 15 30.2 32.2 13 22
D19S433 1 D19S433 2 THO1 1 THO1 2 FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
14 15 6 10 20 20 10 10
D5S818 1 D5S818 2 D7S820 1 D7S820 2 D13S317 1 D13S317 2 TPOX 1 TPOX 2
10 13 9 12 12 13 8 8
Blood group genotyping
RhD RhC Rhc RhE Rhe Fy a Fy b Fy GATA
pos pos pos neg pos neg pos neg
Jka Jkb K k M N S s
neg pos neg pos pos pos pos pos
Kp a Kp b Do a Do b ABO
neg pos neg pos BB
HLA tissue typing
HLA class I type HLA-A*01, A*02; B*07, B*08; Cw*07
HLA class II type HLA-DRB1*01, DRB1*15; DRB5*01; DQB1*05, DQB1*06
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The cell line was analysed for genome stability by G-banding and
showed a normal 46XYmale genotype (Fig. 4). SNP genotypingwas car-
ried out using the Illumina HumanCytoSNP-12 v2.1 BeadChip and re-
vealed a 120 kb region deleted on chromosome 8q24.23 as described
in Canham et al. (2015). In addition to containing no protein coding
genes, this region has been observedmany times in healthy individuals,
occurring with a frequency of 3.85% as documented in the Database of
Genomic Variants (MacDonald et al. 2014).
Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to
fertilise/develop embryos was approved by The Scotland A Research
Ethics Committee and local ethics board at participating fertility clinics
and conducted under licence no. R0136 from the UK HFEA with in-
formed donor consent. The processing and storage of hESC cells for
human application was conducted under licence number 22631 from
the UK Human Tissue Authority.
Cell culture
Fresh embryos were cultured EmbryoAssist (Origio (Medicult),
Denmark) until Day 3 and BlastAssist (Origio) after Day 3 of develop-
ment. Embryos were cultured at 36.5–37.5 °C, 5.0 ± 0.5% CO2, 5.0 ±
0.5% O2 in drops under parafﬁn oil (Origio) and transferred to freshme-
dium at least every 2–3 days.
By Day 8 of development, embryos were placed in derivation condi-
tions consisting of mitotically inactivated GMP grade neonatal human
dermal ﬁbroblasts (HDFs) (Forticell Biosciences, NJ, USA) on tissue cul-
ture plastic in XF KODMEM medium (Knockout-DMEM, 15% KOSR-XF,
2 mM L-glutamine, 1% MEM Non essential amino acids, 2% XF Growth
Factor Cocktail, 0.1 mM β-mercaptoethanol (ThermoFisher Scientiﬁc,
Paisley, UK) supplemented with 80 ng/ml human bFGF (ThermoFisher
Scientiﬁc). When available, cell therapy system quality reagents were
used. If required, assisted hatching was performed by removing thezona pellucidae mechanically using Swemed cutting tools (Vitrolife,
Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% Pharma
grade FCS (GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-
glutamine (ThermoFisher Scientiﬁc). HDF were mitotically inactivated
using gamma irradiation at 50 Gy using a Gammacell Elite 1000 ma-
chine. For use as a feeder layer, irradiated HDFs were plated at
50,000 cells/cm2 in XF KODMEM medium supplemented with
80 ng/ml human bFGF (ThermoFisher Scientiﬁc). Cells were cultured
at 36.5–37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 and 50% medium ex-
changed 6 days a week.
The established cell line was expanded and banked using CellStart
matrix and Stempro hESC Serum Free Medium (cell therapy system
quality reagents, ThermoFisher Scientiﬁc). This contained BSA from a
TSE-free country of origin. Passaging was performed mechanically
using an EZ passage tool (ThermoFisher Scientiﬁc). hESC lines were ex-
panded to 25–30 wells of a 6-well plate and cryopreserved in 0.5–1 ml
Cryostor CS10 (Biolife Solution, Washington, USA) using an EF600–107
controlled rate freezer (Grant Instruments, Cambridge, UK) before
being stored in a− 150 °C freezer (Panasonic Biomedical, Loughbor-
ough, UK).
Mycoplasma
In process mycoplasma detection was performed using Applied
Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and
MicroSEQ™Mycoplasma Real-Time PCR Detection Kit (ThermoFisher
Scientiﬁc (Applied Biosystems)) according to the manufacturer's in-
struction. Eurpoean pharmacopoeia (EP) mycoplasma testing was car-
ried out by Moredun Scientiﬁc Ltd. (Edinburgh, UK), under a quality
and technical agreement.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according to
the manufacturer's instructions. Brieﬂy, an unknown sample was com-
pared with a standard curve of known levels of control endotoxin. An
assay was deemed valid if the coefﬁcient of correlation, r ≥ 0.980 and
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negative control was greater than the reaction time of the lowest stan-
dard on the standard curve.Flow cytometry
Pluripotency was determined using the Human andMouse Pluripo-
tent StemCell Analysis kit (BD,Oxford, UK). Oct 3/4 and SSEA-4were in-
cluded as pluripotencymarkers, and SSEA-1 as a differentiationmarker.
FITC conjugated Tra-1-60 (BD) was used as an additional pluripotency
marker. Fixed and permeabilised cells were analysed using a FACS
Aria ﬂow cytometer (BD) or a Guava easyCyte ﬂow cytometer
(Millipore, Watford, UK). Percentage expression of each marker was
compared to isotype control or unstained cells.Viability
Viability was determined using the Guava ViaCount assay. Brieﬂy,
the Guava Viacount reagent (Millipore) containing a nuclear and a via-
bility dye, was mixed with a single cell suspension, incubated for 5 min
and analysed using the Guava easyCyte ﬂow cytometer (Millipore).
Total cell count, viable cell count and percentage viable cells was
obtained.In vitro differentiation
hESCs were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) and embryoid bodies
(EBs) generated in ultra low attachment plates (Corning) for 7 days be-
fore being transferred into EBmedium (20% FBS (GE Healthcare (PAA)),
80% KO-DMEM 1 mM L-glutamine, 3.5 μM β-mercaptoethanol, 1% non-
essential amino acids (all ThermoFisher Scientiﬁc)), on glass slide tissue
culture chambers (Nunc, ThermoFisher Scientiﬁc) coated with 0.2% gel-
atin (Sigma Aldrich, Dorset, UK) at 0.1 ml/cm2 for 14 days.Fig. 4. RCe013-A (RC-9) at passage 28 was analysed by Giesma staining of 30 mImmunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde (ThermoFisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher Scien-
tiﬁc) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000;
Sigma) and muscle-speciﬁc actin (1:50; DAKO, Glostrup, Denmark)
and secondary antibody anti mouse IgG-AlexaFluor 488 (1:200;
Sigma). Images were acquired using a Zeiss S100 Axiovert ﬂuorescence
microscope or Nikon eC1 confocal microscope.
In vivo differentiation
The developmental potential of hESC lines to form teratomas
consisting of tissues representative of all three germ layers was evaluat-
ed following transplantation under kidney capsule in NOD scid gamma
mice. After three months, the animals were culled and assessed for ter-
atoma formation. Teratomas were ﬁxed in 4% paraformaldehyde, em-
bedded in parafﬁn wax and serial sections of 7 μm thickness were cut
according to standard procedures. For histological assessment, the tis-
sue sections were dewaxed, rehydrated and stained withMasson stain-
ing. Tissue sections were analysed using bright ﬁeld and microscopy
and digital images were recorded.
SNP genotyping and analysis
DNA samples were assayed using the Illumina HumanCytoSNP-12
v2.1 BeadChip. Genotyping data was initially assessed using
GenomeStudio genotyping module (v1.94, Illumina). Karyostudio
(v1.4, Illumina) was employed to perform automatic normalisation
and to identify genomic aberrations utilising default settings of the
built-in cnvPartition algorithm (3.07, Illumina) to generate B-allele fre-
quency and smoothened Log R ratio plots for detected regions. These
parameters are designed to detect CNVs greater than 75 kb and CN-
LOH regions larger than 1 MB with a conﬁdence value greater than 35.
All identiﬁed regions were ﬁrst cross-matched to the Database of Geno-
mic Variants (DGV; http://dgv.tcag.ca) to identify naturally-occurringetaphase spreads and showed a normal 46XY male karyotype at banking.
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DGVwere then checked against a list of ES cell-associated culture adap-
tation genomic variants published by the International Stem Cell Initia-
tive (Amps et al. 2011). See also Canham et al. 2015 for further details.
Genomic analysis and outsourced assays
All outsourced assayswere carried out under a Quality and Technical
Agreement. DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Manchester, UK) according to manufacturer's recommenda-
tions and provided in recommended quantities to the service providers.
Microsatellite PCR, or Short TandemRepeat analysis, was used to de-
termine cell line identity and was carried out by Public Health England.
A proﬁle was obtained for the following core alleles: vWA, D16S539,
Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular Diagnos-
tics laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory
(London, UK) or the Western General Cytogenetics Laboratory (Edin-
burgh, UK). Live cells at 60–70% conﬂuency were shipped in warm con-
tainers, ﬁxed and analysed by standard G-banding analysis. For clinical
grade lines, 30 spreads were analysed.
Viral screening for cytomegalovirus (CMV), Human T-cell
lymphotropic virus (HTLV), Human immunodeﬁciency virus (HIV)-1,Hepatitis C virus (HCV), Hepatitis B virus (HBV), Epstein–Barr virus
(EBV) and syphilis was carried out by The Doctors Laboratory.
Eurpoean pharmacopoeia (EP) sterility testing was carried out by
Moredun Scientiﬁc Ltd. using the culture method.
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